Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
The original release is unavailable here.
Earlier from CDT Equity
- Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
- Conduit Progresses Phase II of its AI Initiative with Sarborg
- Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
- Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
- Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
Later from CDT Equity
- Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
- Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
- Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
- Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
- Conduit Pharmaceuticals Announces Leadership Changes
Follow CDT Equity into a list and get an email when it puts out news.
Follow CDT Equity